SEC Company Response from ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Jun 21, 2019
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: June 21, 2019 · CIK: 0001281895 · Accession: 0001140361-19-011328
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232168
Letter
The Empire State Building
350 Fifth Avenue, Suite 7530
New York, NY 10118
Tel: (646) 440-9100
Fax: (646) 224-9585
June 21, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Donald Field
Re:
Rocket Pharmaceuticals, Inc. Acceleration Request
Acceleration Request
Requested Date:
June 24, 2019
Requested Time:
4:00 p.m. Eastern Time
Ladies and Gentlemen:
Rocket Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the Company’s Registration Statement on Form S-3 (File No. 333-232168), as amended, effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Andrew D. Thorpe, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Mr. Thorpe at (415) 773-5970.
[Signature page follows]
Sincerely,
ROCKET PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
The Empire State Building
350 Fifth Avenue, Suite 7530
New York, NY 10118
Tel: (646) 440-9100
Fax: (646) 224-9585
June 21, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Donald Field
Re:
Rocket Pharmaceuticals, Inc. Acceleration Request
Acceleration Request
Requested Date:
June 24, 2019
Requested Time:
4:00 p.m. Eastern Time
Ladies and Gentlemen:
Rocket Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take
appropriate action to declare the Company’s Registration Statement on Form S-3 (File No. 333-232168), as amended, effective at the “Requested
Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Andrew D. Thorpe, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington &
Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Mr. Thorpe
at (415) 773-5970.
[Signature page follows]
Sincerely,
ROCKET PHARMACEUTICALS, INC.
By:
/s/ John Militello
Name: John Militello
Title: Controller, Principal Financial and Accounting Officer
cc:
Andrew D. Thorpe, Orrick, Herrington & Sutcliffe, LLP